

ASX RELEASE

30 OCTOBER 2024

NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES

**AMPLIA ANNOUNCES UP TO A\$13M CAPITAL RAISING TO SUPPORT COMPLETION OF THE PHASE 2a ACCENT TRIAL IN PANCREATIC CANCER**

**HIGHLIGHTS**

- *Capital raise of up to \$13.0 million (the **Capital Raise**) to support completion of the Phase 2a ACCENT trial in pancreatic cancer with the Company's lead compound narmafotinib and undertaking of a trial in the US in combination with FOLFIRINOX. The Capital Raise comprises:*
  - *a 1 for 6.45 pro-rata accelerated non-renounceable entitlement offer to eligible Amplia shareholders to raise up to approximately A\$4.9 million (**Entitlement Offer**);*
  - *an institutional placement (**Placement**) to raise up to approximately A\$7.8 million utilising Amplia's existing placement capacity under Listing Rules 7.1 and 7.1A;*
  - *a placement to each of the Amplia Directors (**Director Placement**) to raise an aggregate amount of \$325,000, subject to shareholder approval for the purposes of Listing Rule 10.11; and*
  - *three (3) free attaching options for every four (4) new shares issued pursuant to the Entitlement Offer, Placement and Director Placement (subject to shareholder approval in respect of the Placement and Director Placement) (**Attaching Options**). The Attaching Options will have an exercise price of \$0.1725 and will expire 31 October 2027.*
- *Up to approximately 113.2 million new fully paid ordinary shares in Amplia (**New Shares**) to be issued under the Capital Raise, representing approximately 41.2% of Amplia's current shares on issue.*
- *New Shares issued under the Placement, Director Placement and Entitlement Offer are priced at \$0.115 each (**Offer Price**).*
- *Following the Capital Raise the Company intends on executing its strategy to complete the ACCENT trial currently being undertaken in Australia and South Korea and to commence a trial in the US of narmafotinib in combination with FOLFIRINOX.*

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that it is undertaking a Placement, Director Placement and Entitlement Offer to raise up to A\$13.0 million (**Capital Raise**).

Up to approximately 113.2 million New Shares will be issued under the Capital Raise, which represents approximately 41.2% of the current number of Amplia shares on issue. In addition, the Company will issue up to approximately 84.9 million Attaching Options (subject to shareholder approval).

Level 17, 350 Queen Street, Melbourne VIC 3000

Email [info@ampliatx.com](mailto:info@ampliatx.com)

[www.ampliatx.com](http://www.ampliatx.com)

The offer price per New Share (**Offer Price**) under the Capital Raise is \$0.115, which represents a:

- 14.8% discount to the last closing price of ATX's shares on Tuesday, 29 October 2024 (being \$0.135);
- 18.6% discount to the 5-day VWAP up to 29 October 2024 (being \$0.141); and
- 22.3% discount to the 10-day VWAP up to 29 October 2024 (being \$0.148).

The New Shares issued under the Capital Raise will be issued on the same terms as, and will rank equally with, all existing Amplia shares (save that the New Shares are entitled to be issued Attaching Options).

The funds raised from the Capital Raise will be used by ATX to support

the completion of the ACCENT trial of the Company's lead compound, narmafotinib (the best-in-class Focal Adhesion Kinase (FAK) inhibitor) in pancreatic cancer, undertake a clinical trial in the US of narmafotinib in combination with FOLFIRINOX in pancreatic cancer (cleared IND from FDA for US-based trial) and general administrative and working capital.

Bell Potter Securities Limited (ACN 006 390 772, AFSL 243480) (**Bell Potter**) and Taylor Collison Limited (ACN 008 172 450, AFSL 247083) (**Taylor Collison**) are acting as joint lead managers and bookrunners for the Capital Raise (**Joint Lead Managers**).

The Company's sources and uses of funds are detailed below:

Sources of funds	Amount	Use	Amount
Cash Balance*	\$4.6m	ACCENT Trial Costs	\$5.9m
Anticipated R&D Tax Rebate**	\$4.0m	FOLFIRINOX <ul style="list-style-type: none"> <li>• Trial Costs</li> <li>• Shipping</li> <li>• Pharmacokinetic / Pharmacodynamic modelling</li> </ul>	\$6.3m
Capital Raise proceeds^	\$13.0	CMC Follow-on studies	\$1.9m
		Operations, pre-clinical, working capital	\$6.7m
		Offer costs	\$0.8m
<b>Total</b>	<b>\$21.6m</b>	<b>Total</b>	<b>\$21.6m</b>

\* Cash balance as at 30 September 2024.

\*\* Subject to approval – expected August 2025. See 'R&D Tax Rebate' in Key Risks in Investor Presentation.

^ Assumes the Entitlement Offer and Placement are fully subscribed and the Director Placement is approved – see 'Risks Associated with the Offer' in Key Risks.

## **Capital Raise details:**

### **Placement**

The Placement will be conducted under Amplia's available capacity under ASX Listing Rules 7.1 and 7.1A and is expected to raise up to approximately A\$7.8 million in gross proceeds.

The New Shares under the Placement are expected to be issued on Thursday, 7 November 2024.

### **Director Placement**

All of Amplia's Directors have committed to subscribe for New Shares pursuant to the Director Placement, as follows:

- Dr Warwick Tong has committed to subscribe for \$80,000 worth of New Shares (being 695,652 New Shares and 521,739 Attaching Options);
- Dr Robert Peach has committed to subscribe for \$125,000 worth of New Shares (being 1,086,957 New Shares and 815,218 Attaching Options);
- Dr Chris Burns has committed to subscribe for \$40,000 worth of New Shares (being 347,826 New Shares and 260,869 Attaching Options); and
- Ms Jane Bell has committed to subscribe for \$80,000 worth of New Shares (being 695,652 New Shares and 521,739 Attaching Options).

The Director Placement is expected to raise a total of \$325,000 via the issue of 2,826,087 New Shares. In addition, a total of 2,119,566 Attaching Options are expected to be issued to the Directors.

The Director Placement is conditional on shareholder approval at a General Meeting to be held on or around Monday, 9 December 2024 (**EGM**).

### **Entitlement Offer**

The Entitlement Offer is a pro-rata accelerated non-renounceable entitlement offer to eligible Amplia shareholders (**Eligible Shareholders**) at the Offer Price to raise up to approximately A\$4.9 million. All Eligible Shareholders will have the opportunity to apply for 1 New Share for every 6.45 shares they hold as at the Record Date (being 7:00pm (Sydney time) on Friday, 1 November 2024).

The Entitlement Offer comprises both the Institutional Entitlement Offer and the Retail Entitlement Offer (each described below).

All New Shares issued to Eligible Shareholders under the Entitlement Offer will be issued at the Offer Price. The Entitlement Offer is non-renounceable and entitlements will not be tradeable on the ASX or be otherwise transferable. Eligible Shareholders who do not take up their full entitlement will not receive any payment and their interest in ATX will be diluted.

The Entitlement Offer will be undertaken pursuant to a transaction-specific prospectus lodged with ASIC and ASX on 30 October 2024 (**Prospectus**).

### ***Institutional Entitlement Offer***

The Institutional Entitlement Offer is being conducted on Wednesday, 30 October and Thursday, 31 October 2024. Certain institutional, professional, and sophisticated investors who are holders of ATX shares (**Eligible Institutional Shareholders**) may receive an offer to participate in the Institutional Entitlement Offer.

Under the Institutional Entitlement Offer, Eligible Institutional Shareholders can choose to take up all, part or none of their entitlement. Any New Shares not allocated to Eligible Institutional Shareholders will be placed on a best endeavours basis by the Joint Lead Managers.

Further details regarding the eligibility of Amplia's institutional shareholders to participate in the Entitlement Offer are provided in the Prospectus.

### ***Retail Entitlement Offer***

Eligible retail shareholders with a registered address in Australia or New Zealand as at the Record Date (**Eligible Retail Shareholders**) have the opportunity to take up their entitlement for New Shares at the Offer Price, on the terms and conditions set out in the Prospectus.

The Retail Entitlement Offer will open on Wednesday, 6 November 2024 and is anticipated to close on Friday 22 November 2024.

Eligible Retail Shareholders can choose to take up all, part, or none of their entitlements. Furthermore, the Retail Entitlement Offer will include a 'Top Up Facility' under which Eligible Retail Shareholders who take up their entitlement in full may also apply for additional New Shares (and Attaching Options) (**Top-Up Facility**). Further details are provided in the Prospectus and your personalized Entitlement and Acceptance Form.

There is no guarantee that applicants under the Top-Up Facility will receive all or any of the additional New Shares for which they apply. New Shares allocated under the Top-Up Facility will be allocated in accordance with the allocation policy outlined in the Prospectus.

Any shortfall from the Retail Entitlement Offer will be placed by the Joint Lead Managers within three months of the Closing Date on a best endeavours basis via a Shortfall Offer which is described in the Prospectus.

New Shares under the Retail Entitlement Offer are expected to be issued on Friday 29 November 2024. Please note that Amplia's retail shareholders with a registered address outside Australia or New Zealand on the Record Date are ineligible to participate in the Retail Entitlement Offer for the reasons set out in the Prospectus. Securityholders who are on the register on the Record Date will be notified by ATX if they are ineligible to participate in the Entitlement Offer.

Further details regarding how to apply for New Shares in the Retail Entitlement Offer is set out in the Prospectus and will be provided in your personalized Entitlement and Acceptance Form.

### **Attaching Options**

New Shares issued under the Placement, Director Placement and Entitlement Offer will be offered with three (3) free attaching options for every four (4) New Shares issued ("**Attaching Options**"). The Attaching Options will have an exercise price of A\$0.1725 and will expire on 31 October 2027.

Amplia will apply for quotation of the Attaching Options on the ASX. Quotation of the Attaching Options is subject to the Company satisfying ASX's quotation requirements.

The Director Placement (including the offer of Attaching Options) and the offer of Attaching Options to participants in the Placement, is conditional on Amplia shareholder approval at the EGM.

The offer of Attaching Options to Directors and Placement participants will be made pursuant to the Prospectus.

### Key dates for Capital Raise

The Capital Raise will be conducted according to the following indicative timetable:

Event	Date
Trading halt and announcement of Capital Raise Prospectus lodged with ASIC and released to ASX	Wednesday, 30 October 2024
Placement & Institutional Entitlement Offer opens	Wednesday, 30 October 2024
Placement & Institutional Entitlement Offer closes	Thursday, 31 October 2024
Announcement of results of Placement and Institutional Entitlement Offer and trading halt lifted	Friday, 1 November 2024
Record date for Entitlement Offer (7.00pm Sydney time)	Friday, 1 November 2024
Settlement of New Shares issued under the Placement and Institutional Entitlement Offer	Wednesday, 6 November 2024
Entitlement and Acceptance Forms made available to Eligible Retail Shareholders and Retail Entitlement Offer opens	Wednesday, 6 November 2024
Issue of New Shares under the Placement and Institutional Entitlement Offer and Attaching Options under the Institutional Entitlement Offer	Thursday, 7 November 2024
Retail Entitlement Offer closes (5.00pm Sydney time)	Friday, 22 November 2024
Announcement of results of Retail Entitlement Offer	Wednesday, 27 November 2024
Settlement of Retail Entitlement Offer	Thursday, 28 November 2024
Issue of New Shares and Attaching Options under the Retail Entitlement Offer	Friday, 29 November 2024
Commencement of trading of New Shares issued under the Retail Entitlement Offer	Monday, 2 December 2024
EGM to approve the Director Placement and issue of Attaching Options to Placement participants	On or around Monday, 9 December 2024
Allotment of Attaching Options to Placement participants and New Shares and Attaching Options to Directors (subject to Shareholder approval)	On or around Tuesday, 10 December 2024
Commencement of trading of Attaching Options (subject to satisfaction of quotation conditions)	On or around Thursday, 12 December 2024

\* Please note the dates set out above are indicative only and are subject to change. All dates and times are references to Sydney, Australia time.

Amplia shares will remain in a trading halt pending announcement of the results of the Placement and Institutional Entitlement Offer.

## Prospectus and Investor Presentation

This announcement is not a disclosure document and should not be considered as investment advice. The information contained in this announcement is for information purposes only and should not be considered an offer or an invitation to acquire Company securities or any other financial products and does not form part of any contract for the acquisition of securities.

A transaction-specific prospectus containing information in respect of the Entitlement Offer and the offer of Attaching Options to participants in the Placement and Director Placement was lodged with ASIC and ASX today (Wednesday, 30 October 2024).

Eligible Shareholders and Placement and Director Placement participants should read the Prospectus in full before deciding whether to subscribe for New Shares and Attaching Options.

Eligible Retail Shareholders will be able to access their Entitlement and Acceptance Form from Computershare's Investor Centre: [www.investorcentre.com/au](http://www.investorcentre.com/au). The Entitlement and Acceptance Form will be accompanied by the Prospectus. Instructions on how to apply for New Shares and Attaching Options are provided in the Prospectus and will be provided in Entitlement and Acceptance Forms provided for each Eligible Retail Shareholder.

Further information regarding the Company and the Capital Raise, including a description of the risks associated with an investment in the Company and a detailed use of funds, is provided in the Prospectus and an investor presentation, each of which was lodged with ASX today and is available at [www.asx.com.au](http://www.asx.com.au).

---

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics Limited.

### About Narmafotinib

Narmafotinib (AMP945) is the Company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic and other cancers, and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. The drug has successfully completed a healthy volunteer study, and is currently in an open-label Phase 2a trial in pancreatic cancer where a combination of narmafotinib and the chemotherapies gemcitabine and Abraxane® is being assessed for safety, tolerability and efficacy.

### About the ACCENT Trial

The ACCENT trial is entitled '*A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients*'.

The ACCENT trial explores the use of narmafotinib in combination with standard-of-care chemotherapy of gemcitabine and Abraxane® in first-line patients with advanced pancreatic cancer. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, identified a 400 mg oral daily dose of narmafotinib, given in the days preceding regular chemotherapy infusion, as safe and well tolerated.

This second stage (Phase 2a), of the trial is designed to assess drug efficacy in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival (OS). Safety and tolerability will continue to be assessed.

More information about the ACCENT trial, including a list of participating sites, can be found via the Amplia Therapeutics [website](#) and at ClinicalTrials.gov under the identifier [NCT05355298](#).

**Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

**Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](#) (@ampliatx), [Threads](#) (@ampliatx) and [LinkedIn](#).